drugset
drugset / Trial / NCT01159483

First-in-Human Study of PF-04958242 in Healthy Volunteers

NCT01159483 ↗

Phase 1 Completed 24 enrolled Biogen
RandomizedCrossoverTriple-blindTreatment

Summary

The primary objective of this study will evaluate the safety and tolerability of single, escalating doses of PF-04958242 administered orally to healthy adult participants. This study will also evaluate the plasma pharmacokinetics (PK) of single doses of PF-04958242 after single escalating doses of PF-04958242 administered orally to healthy adult participants.

Timeline

Start
2010-07-15
Primary completion
2010-10-16
Completion
2010-10-16

Drugs

EvaluationDrugModalityDoseRoute
Subject PESAMPATOR Small molecule 0.01 mg Oral
Subject PESAMPATOR Small molecule 0.03 mg Oral
Subject PESAMPATOR Small molecule 0.1 mg Oral
Subject PESAMPATOR Small molecule 0.3 mg Oral
Subject PESAMPATOR Small molecule 0.6 mg Oral
Subject PESAMPATOR Small molecule 1 mg Oral

Indications

No indication recorded.